Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCB099280 |
Synonyms | |
Therapy Description |
INCB099280 is a small molecule inhibitor of CD274 (PD-L1) that prevents binding to PDCD1 (PD-1), potentially inducing an anti-tumor immune response (J ImmunoTherapy Cancer 2022;10, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB099280 | INCB 099280|INCB-099280|INCB 99280|INCB-99280|INCB99280 | Immune Checkpoint Inhibitor 149 | INCB099280 is a small molecule inhibitor of CD274 (PD-L1) that prevents binding to PDCD1 (PD-1), potentially inducing an anti-tumor immune response (J ImmunoTherapy Cancer 2022;10, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04242199 | Phase I | INCB099280 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | FRA | BEL | AUS | 1 |
NCT05888844 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Active, not recruiting | TUR | ROU | NZL | HUN | HRV | FRA | ESP | CAN | BRA | AUS | 5 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT06337162 | Phase I | INCB099280 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) (HCC) | Withdrawn | USA | 0 |